Aerovate Therapeutics to Merge with Jade Biosciences

Welltower (Affiliate) to Acquire NorthStar Healthcare Income; TPG to Acquire Altus Power; Jade Biosciences to Merge with Aerovate Therapeutics (Plus KVAC/ Madera SPAC Merger)

March 18, 2025

Healthcare Services

The announcement flags multiple pending M&A actions in which NorthStar Healthcare Income is proposed to be acquired by an affiliate of Welltower for $3.03 per share in cash, Altus Power is proposed to be acquired by TPG for $5.00 per share in an all-cash deal, and Aerovate Therapeutics is proposed to merge with Jade Biosciences. It also references Keen Vision Acquisition Corp. in connection with a proposed merger with Madera Inc.

Axcelis Technologies and Veeco Instruments to Combine in All-Stock Merger

October 1, 2025

IT Services

Axcelis Technologies and Veeco Instruments have entered into a definitive agreement to combine in an all-stock merger. The transaction is expected to close in the second half of 2026, subject to shareholder approvals, regulatory approvals, and customary closing conditions.

BT Brands and Aero Velocity Execute Definitive Merger Agreement

September 3, 2025

IT Services

BT Brands, Inc. (Nasdaq: BTBD) and Aero Velocity Inc. entered into a definitive merger agreement in an all-stock transaction to combine the companies. The combined company will focus on advanced drone technologies and AI-powered solutions for government and commercial applications, with Aero Velocity continuing as a wholly-owned subsidiary of BT Brands; closing is expected in Q4 2025 or Q1 2026.

Vertex Pharmaceuticals Acquires ViaCyte for $320M

July 11, 2022

Biotechnology

Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.

Candid Therapeutics to Merge With Rallybio (Creating Nasdaq-listed Candid Therapeutics)

March 5, 2026

Biotechnology

Clinical-stage biotechnology company Candid Therapeutics signed a merger agreement with Rallybio Corporation to create a combined company focused on developing T cell engager therapies for autoimmune diseases. The transaction is expected to close in mid-2026, pending customary approvals and conditions, and Candid also secured an oversubscribed private financing of more than $505 million led by healthcare institutional investors.

biote Corp Acquires Asteria Health

January 17, 2024

Healthcare Services

biote Corp. (NASDAQ: BTMD) announced a definitive agreement to acquire F.H. Investments, Inc., doing business as Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The deal is intended to strengthen biote’s control over its supply chain through vertical integration of hormone product manufacturing and expand biote’s capabilities in 503B manufacturing and product development.